[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-cancer-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-cancer-diagnosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,42,68,95,120,144,175,199,222,247,268,293,320,340],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100559048","evaluating-the-implementation-of-a-comprehensive-multilevel-virtual-oncology-program-among-veterans-diagnosed-with-lung-colorectal-prostate-and-breast-cancers-in-the-us-department-of-veterans-affairs-100559048",false,"NCT06559059","Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs","Patients Inclusion Criteria:\n\n1. A Veteran\n2. Aged 18 years or older\n3. Newly diagnosed with lung, prostate, breast, or colon cancer within 3 months of telemedicine visit\n4. Engaged in an oncology visit during the 36-month analysis period at a Veterans Affairs Medical Center (VAMC) location.\n\nVAMC Providers and Staff Inclusion Criteria:\n\n1. Provider or staff member at one of the VAMC locations including physicians, nurse practitioners, physicians' assistants, and nurses caring for Veterans\n2. Providers or staff members having helped provide care for at least 5 Veterans with cancer in the previous 6 months at a VAMC location\n\nPatients Exclusion Criteria:\n\n1. Veterans who have not seen any providers in the VA within the past year\n2. Patients previously diagnosed with lung, prostate, breast, or colon cancer\n3. Pregnant patients\n\nVAMC Providers and Staff Exclusion Criteria:\n\n1\\. Providers or staff members who do not help treat Veterans with specified cancers in oncology at the VA","ALL","18 Years",{"count":18,"type":19},1800,"ESTIMATED","INTERVENTIONAL",[22],"NA","The objective of the pragmatic trial to test the effectiveness of an existing, ongoing clinical service, the VA National TeleOncology program (NTO), a multilevel telehealth population health management program. The primary aims are to study the intervention and determine its effectiveness on telehealth engagement, clinical quality, and healthcare cost outcomes across personal characteristics.",[25,26,27,28],"Lung Cancer Diagnosis","Colorectal Cancer (Diagnosis)","Prostate Cancer Diagnosis","Breast Cancer Diagnosis","RECRUITING","2026-06-01",{"date":32,"type":33},"2026-06-03","ACTUAL",{"date":35,"type":33},"2024-06-18",{"date":37,"type":19},"2027-07-31",{"name":39,"class":40},"NYU Langone Health","OTHER",5,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100637201","phase-1-a-phase-i-trial-of-s-adenosylmethionine-same-for-chemoprevention-of-colorectal-adenomas-100637201","NCT07582003","A Phase I Trial of S-Adenosylmethionine (SAMe) for Chemoprevention of Colorectal Adenomas","Inclusion Criteria:\n\n1\\) Adults ≥18 years old with histologically confirmed, curatively resected stage I-II colorectal cancer; 2) must agree to pre-intervention (baseline) stool sample and distal colon biopsy; 3) must start study intervention within 30 days ±7 days of the baseline biopsy; 4) must be able to complete up to 12 months of intervention prior to planned postoperative surveillance colonoscopy within 1 year of surgery; 5) must undergo repeat stool sample and distal colon biopsy within 7 days ±4 days of the last dose of study intervention; 6) did not receive adjuvant therapy; 7) not currently breastfeeding or pregnant.\n\nExclusion Criteria:\n\n1\\) Have a history familial adenomatous polyposis (FAP); 2) have a history of hereditary nonpolyposis colorectal cancer; 3) history of inflammatory bowel disease; 4) high-dose aspirin (except for low-dose (≤100 mg\u002Fday) aspirin for cardiovascular prevention) within the past 60 days of enrollment.",{"count":49,"type":19},18,[51],"PHASE1","This study will enroll a total of 18 patients who have undergone curative surgery for stage I or II colorectal cancer and are planned for post-surgical surveillance without any need for chemotherapy at Cedars-Sinai Medical Center. All subjects will receive an oral daily supplement called S-Adenosylmethionine (SAMe) which has been hypothesized to reduce colorectal polyps (precursors to colorectal cancer) and prevent colorectal cancer formation. The study investigates what the appropriate dosage of SAMe is so that there is the lowest risk of side effects, and whether the supplement will prevent polyp formation in a population of patients who at risk for developing polyps and colorectal cancer. The primary endpoint will be to determine the recommended phase II dose (RP2D), the highest safe dose of SAMe that could be studied in larger clinical trials to advance this agent further in clinical development. Secondary endpoints include safety, the rate of postoperative adenomas detected on surveillance colonoscopy, and the effects of SAMe on the colon, specifically, its impact on gut bacteria and tissue markers before and after SAMe treatment to better understand the mechanisms to how SAMe may have its colorectal cancer preventive effects.",[26,54],"Adenoma",[54,56,57],"Colorectal Cancer","S-Adenosylmethionine (SAMe)","NOT_YET_RECRUITING","2026-05-06",{"date":61,"type":33},"2026-05-12",{"date":30,"type":19},{"date":64,"type":19},"2028-06-01",{"name":66,"class":40},"Jun Gong, MD",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":20,"phases":78,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":67},"100640180","superior-hypogastric-plexus-block-during-laparoscopic-colorectal-cancer-surgery-100640180","NCT07579780","Superior HypogastrIc plExus bLock During Laparoscopic Colorectal Cancer Surgery","Superior Hypogastric Plexus Block for Early Recovery After Laparoscopic Colorectal Cancer Surgery: A Randomized Controlled Trial","SHIELDS","Inclusion Criteria:\n\n* Able to provide informed consent.\n* Undergoing elective laparoscopic radical resection for colorectal cancer.\n* American Society of Anesthesiologists Physical Status (ASA) class I-III.\n\nExclusion Criteria:\n\n* Allergy to block medication (s).\n* Coagulation dysfunction.\n* Local or systemic infection.\n* Unable to cooperate with the completion of the study protocol.",{"count":77,"type":19},170,[22],"This trial seeks to assess the efficacy of a superior hypogastric plexus block for early quality of recovery after laparoscopic colorectal cancer surgery.",[26,81,82],"Laparoscopic Surgery","Superior Hypogastric Plexus Block",[56,84,85,86],"laparoscopic surgery","superior hypogastric plexus block","Quality of recovery","2026-05-05",{"date":61,"type":33},{"date":90,"type":33},"2025-12-15",{"date":92,"type":19},"2027-02-18",{"name":94,"class":40},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":67},"100626045","secondary-care-colorectal-cancer-pathway-review-100626045","NCT07430527","Secondary Care Colorectal Cancer Pathway Review","A Retrospective Review of the Secondary-care Colorectal Cancer Pathway Within NHS Lothian: An Evaluation of 3 Years of Pathway Performance","Inclusion Criteria:\n\nPatients managed within the NHS Lothian CRC USoC\u002Furgent pathway (including urgent referrals) due to 'red-flag' symptoms concerning of CRC from April 2022 to August 2025.\n\nExclusion Criteria:\n\n* Under the age of 18.\n* History of inflammatory bowel disease.\n* Under polyp surveillance.\n* Previous diagnosis of CRC.",true,{"count":104,"type":19},25000,"OBSERVATIONAL","Bowel cancer (colorectal cancer) is the 4th most common cancer in Scotland. Approximately 4,000 cases are diagnosed annually. Cancer-related deaths in Scotland are higher than other UK nations. Improving the early detection of bowel cancer, and therefore survival, is important.\n\nThe majority of bowel cancers are diagnosed within secondary-care (colorectal surgery unit). Upon GP referral to secondary-care, patients provide stool samples which are analysed for microscopic blood (FIT; faecal immunohistochemical test). Patients with a single positive result are more likely to have bowel cancer (0.2% risk if no blood detected, but 8.4% if detected). A positive test triggers further investigation, either CT scan or colonoscopy depending on the result. Currently, colonoscopy and radiology services throughout Scotland are under significant pressure causing delays.\n\nOnly 2% of patients referred to secondary-care are diagnosed with bowel cancer, and most colonoscopies performed do not yield significant findings. We have shown that performing two repeated FITs upon referral improves cancer pickup rate (sensitivity) and reduces missed cancers. We successfully implemented this in NHS Lothian and contributed to national guidelines.\n\nThis study will undertake a comprehensive retrospective review of the double-FIT urgent suspicion of bowel cancer pathway within NHS Lothian, from April 2022 (date of pathway inception) to August 2025, including around 25,000 patients that have been managed through the pathway. We will calculate key performance indicators and diagnostic accuracy of the pathway. Health economic analysis will determine cost-per-diagnosis. Risk factors for bowel cancer in this patient cohort will be identified to develop a support tool for primary and secondary-care. These results will be used to develop a future pathway to optimise pathway efficiency and cancer detection.",[26],[109,110],"Faecal immunohistochemical test","FIT","2026-05-04",{"date":113,"type":33},"2026-05-08",{"date":115,"type":19},"2026-06-30",{"date":117,"type":19},"2030-08-31",{"name":119,"class":40},"University of Edinburgh",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":20,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":142,"locationsCount":67},"100629657","phase-1-effects-of-high-fiber-diet-on-gut-microbiota-metabolism-and-immune-microenvironment-in-solid-tumor-patients-a-clinical-study-100629657","NCT07477522","Effects of High-Fiber Diet on Gut Microbiota, Metabolism, and Immune Microenvironment in Solid Tumor Patients: A Clinical Study","Inclusion Criteria:\n\n* (1) Sign a written informed consent form before any study - related procedures are carried out.\n\n  (2) Males or females, aged 18 - 80 years old. (3) Diagnosed with solid tumors by pathological tissue biopsy. (4) According to the RECIST v1.1 (Response Evaluation Criteria in Solid Tumors Version 1.1) criteria, there is at least 1 measurable lesion (lesions previously treated with local therapies such as radiotherapy cannot be regarded as measurable lesions).\n\n  (5) ECOG (Eastern Cooperative Oncology Group Performance Status) score of 0 - 1.\n\n  (6) NRS - 2002 (Nutritional Risk Screening 2002) score \\\u003C 3. (7) BMI (Body Mass Index) ≥ 18.5 (can be adjusted appropriately according to the actual situation).\n\n  (8) Patients who can eat orally or through a feeding tube and can tolerate enteral nutrition.\n\n  (9) Sufficient organ function, and the subjects need to meet the following laboratory indicators: In the absence of granulocyte - colony - stimulating factor use in the past 14 days, the absolute neutrophil count ≥ 1.5×10⁹\u002FL.\n\nPlatelets ≥ 75×10⁹\u002FL. In the absence of blood transfusion or erythropoietin use in the past 7 days, hemoglobin ≥ 8 g\u002FdL.\n\nSerum albumin ≥ 3.0 g\u002FdL. Total bilirubin ≤ 1.5× the upper limit of normal (ULN). Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5×ULN. In case of liver metastasis, ALT and\u002For AST ≤ 5×ULN, and total bilirubin ≤ 3×ULN. In case of liver or bone metastasis, Alkaline Phosphatase (AKP) ≤ 5×ULN.\n\nCreatinine clearance rate ≥ 50 mL\u002Fmin (calculated according to the Cockcroft - Gault formula) or serum creatinine ≤ 1.5×ULN.\n\nInternational Normalized Ratio (INR) ≤ 1.5×ULN, Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5×ULN.\n\nUrine protein \\\u003C 2+ (if urine protein ≥ 2+, a 24 - hour urine protein quantification can be performed, and subjects with a 24 - hour urine protein quantification \\\u003C 2.0 g can be enrolled).\n\n(10) Women of child - bearing potential must agree to avoid sexual intercourse (heterosexual intercourse) or use a reliable and effective contraceptive method from the signing of the informed consent form until at least 6 months after the last administration of the study drug. In addition, the serum HCG (Human Chorionic Gonadotropin) test must be negative within 3 days before the start of the study treatment, and the subject must be non - lactating. A female patient is considered to be of child - bearing potential if she is post - menopausal but has not reached the post - menopausal state (non - menstrual period ≥ 12 consecutive months, and no other causes are found except menopause) and has not undergone sterilization surgery (such as hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).\n\n(11) If there is a risk of pregnancy, all subjects (regardless of male or female) need to use a contraceptive method with an annual failure rate of less than 1% throughout the treatment period until 120 days after the last administration of the study drug (or 180 days after the last administration of the chemotherapy drug)\n\nExclusion Criteria:\n\n* (1) Patients with cognitive impairment or mental illness who are unable to understand the study content.\n\n  (2) Patients with central nervous system or meningeal metastases. (3) Patients with clinically symptomatic moderate or severe ascites (that is, those who require therapeutic paracentesis within 2 weeks before the start of study treatment; patients with only a small amount of ascites shown on imaging and no clinical symptoms can be enrolled).\n\n  (4) Patients with uncontrolled or moderate to severe pleural effusion and pericardial effusion.\n\n  (5) Patients with severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralytic and mechanical intestinal obstruction; tracheoesophageal fistula, gastrointestinal perforation or gastrointestinal fistula, or abdominal abscess; patients with extra - gastrointestinal bleeding with a CTCAE (Common Terminology Criteria for Adverse Events) grade 3 or above within 6 months before the start of study treatment or grade 2 or above within 3 months (such as abnormal vaginal bleeding, hematemesis).\n\n  (6) Patients known to be allergic to the active ingredients or excipients of the study drug.\n\n  (7) Patients with poorly controlled diabetes. (8) Patients with poorly controlled hypertension (systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg under routine antihypertensive treatment), with a history of hypertensive crisis or hypertensive encephalopathy.\n\n  (9) Patients with severe cardiovascular and cerebrovascular diseases, including cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarction, and major vascular diseases within 6 months before enrollment (including but not limited to aortic aneurysms requiring surgical repair or recent arterial thrombosis); patients with poorly controlled clinical symptoms or heart diseases, such as unstable angina pectoris, NYHA (New York Heart Association) heart failure grade II or above, left ventricular ejection fraction \\\u003C 50% on color Doppler echocardiography, or severe arrhythmias that cannot be controlled by drug treatment.\n\n  (10) Pregnant or lactating women. (11) Other situations considered by the investigator as inappropriate for enrollment.","75 Years",{"count":128,"type":19},25,[51],"Cancer remains a major global public-health challenge and a central focus of medical research. According to the International Agency for Research on Cancer (IARC, 2020), 19.29 million new malignant tumors and 9.96 million cancer deaths occurred worldwide, \\>90 % being solid cancers. Lung cancer alone accounted for 2.2 million new cases and 1.8 million deaths; \\>75 % of patients were already at an advanced stage at diagnosis. Current options for late-stage solid tumors are limited: surgery is often impossible because of metastasis; cytotoxic chemotherapy produces dose-limiting toxicities (grade Ⅲ-Ⅳ myelosuppression 15-40 %, mucositis 50-80 %); radiotherapy risks pneumonitis (5-15 %) or enteritis (5-20 %) when tumors abut vital organs; targeted agents succumb to acquired resistance after a median 9-13 months; and immune-checkpoint inhibitors achieve \\\u003C40 % objective response with 7-15 % grade 3-4 immune-related adverse events.\n\nDietary intervention is therefore emerging as a promising adjunct. Dietary fibre protects against cardiovascular and metabolic diseases, yet intake is universally low. WHO and the Chinese Nutrition Society recommend 25-30 g total fibre per day (≈15-21 g insoluble), whereas Chinese adults consume only \\~11 g insoluble fibre. High-fibre diets reshape gut microbiota, augment short-chain fatty acid (SCFA) production, strengthen intestinal barrier function, activate CD8⁺ T cells and dampen regulatory T cells, thereby enhancing anti-tumour immunity. A melanoma cohort showed improved progression-free survival under immunotherapy when fibre intake was high. Similar microbiota-immune axes may operate in colorectal and other solid cancers, but clinical data are scarce.\n\nWe therefore propose a study to examine whether a high-insoluble-fibre diet (\\>21 g\u002Fday) modulates gut-microbiota composition, metabolite profiles and peripheral-blood immune subsets in solid-tumour patients, and to evaluate consequent effects on treatment response and quality of life. The findings will clarify whether fibre-driven microbiota-immune crosstalk can be harnessed as a personalised nutritional strategy to improve cancer outcomes.",[26,132,133],"Diet Habits","High-fibre Diet",[135,56],"high-fibre diet","2026-03-12",{"date":138,"type":33},"2026-03-17",{"date":140,"type":33},"2025-10-31",{"date":115,"type":19},{"name":143,"class":40},"West China Hospital",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":20,"phases":154,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":67},"100628667","virtual-vs-physical-art-therapy-for-anxiety-psychological-well-being-and-sleep-quality-in-colorectal-cancer-patients-100628667","NCT07464626","Virtual vs Physical Art Therapy for Anxiety, Psychological Well-being, and Sleep Quality in Colorectal Cancer Patients","Effects of Virtual Art Therapy Delivered Through Virtual Reality Glasses and Physical Art Therapy on Anxiety, Psychological Well-being, and Sleep Quality in Patients With Colorectal Cancer: A Randomized Controlled Trial","PVART-CRC","Inclusion Criteria Age 18 years or older Diagnosed with colorectal cancer Receiving outpatient chemotherapy (FOLFOX or XELOX regimen) ECOG performance status between 0 and 2 Not receiving radiotherapy No hearing or speech impairments No severe psychiatric disorders (e.g., schizophrenia, major depression, bipolar disorder) Able to understand the study procedures and provide informed consent Willing to participate in the study Exclusion Criteria ECOG performance status of 3 or higher Patients who do not meet the inclusion criteria Patients unwilling to participate in the study",{"count":153,"type":19},78,[22],"This randomized controlled trial aims to evaluate the effects of virtual reality-based art therapy and physical art therapy on anxiety, psychological well-being, and sleep quality in patients with colorectal cancer receiving outpatient chemotherapy. A total of 78 patients will be randomly assigned to three groups: a virtual reality art therapy group, a physical art therapy group, and a control group. Participants in the intervention groups will receive art therapy sessions every two weeks for eight weeks (four sessions in total). Anxiety, psychological well-being, and sleep quality will be assessed using validated scales before the intervention and after the fourth session. The findings are expected to contribute to the development of non-pharmacological supportive care interventions for oncology patients.",[26,157,158],"Anxiety","Sleep Disturbance",[160,161,162,163,164,165],"Art Therapy","Virtual Reality Art Therapy","Psychological Well-being","Sleep Quality","Cancer Supportive Care","Non-pharmacological Intervention","2026-03-07",{"date":168,"type":33},"2026-03-11",{"date":170,"type":33},"2026-03-01",{"date":172,"type":19},"2027-12-30",{"name":174,"class":40},"Dokuz Eylul University",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":20,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":67},"100620742","study-comparing-the-quality-of-colon-cleanliness-with-prepackaged-lrd-low-residue-diet-vs-guided-pog-100620742","NCT07361575","Study Comparing the Quality of Colon Cleanliness With Prepackaged LRD (Low-residue Diet) vs. Guided (POG).","A Single-blind, Randomized Study Comparing the Quality of Colon Cleanliness With Prepackaged LRD (Low-residue Diet) vs. Guided (POG).","POG","Inclusion Criteria:\n\n* Patient of one of the investigators for total colonoscopy (no prior colonic surgery);\n* Patient aged 18 years or older;\n* Patient classified as ASA 1, ASA 2, or ASA 3;\n* Not participating in any other current clinical trial;\n* Free, informed, and signed consent;\n* Patient affiliated with or a beneficiary of a social security scheme, according to Article L.1124-1 of the French Public Health Code;\n\nExclusion Criteria:\n\n* Patient taking major psychotropic medications;\n* Patient with uncontrolled diabetes;\n* Patient with coagulation abnormalities preventing polypectomy: PT \\\u003C50%, Platelets \\\u003C50,000\u002Fmm³, current effective anticoagulation therapy (clopidogrel, prasugrel, or ticagrelor);\n* Patient referred for removal of a known polyp;\n* Chronic inflammatory bowel disease;\n* Known colonic stenosis;\n* Diverticulitis of less than 6 weeks duration;\n* Pregnant, parturient, or breastfeeding woman;\n* Patient deprived of liberty by administrative or judicial order, or under guardianship or limited legal protection;\n* Patient unable to understand the objectives and constraints of the study.",{"count":184,"type":19},230,[22],"Low-residue diet (LRD) in patient improves the quality of the colon cleanliness and thus the adenoma detection rate (ADR). This is a key criterion in colonoscopy screening for colorectal cancer (CRC). The benefit of an LRD lasting more than 24 hours before colonoscopy has not been demonstrated compared to a 24-hour LRD.\n\nFew studies have evaluated the benefit of a prepackaged 24-hour LRD compared to simply receiving oral and written LRD instructions during a consultation.\n\nThe aim of the study is to evaluate the usefulness of a prepackaged LRD (Colobox®) compared to simple LRD instructions on colon cleanliness (Boston score) in patients examined by endoscopy.",[188,26,189],"Colorectal Cancer Prevention","Colorectal Adenocarcinoma","2026-02-13",{"date":192,"type":33},"2026-02-17",{"date":194,"type":19},"2026-01-30",{"date":196,"type":19},"2026-11-30",{"name":198,"class":40},"Clinique Paris-Bercy",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":20,"phases":208,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":67},"100621903","effects-of-a-whatsapp-assisted-prehabilitation-for-patient-undergoing-elective-colorectal-cancer-surgery-100621903","NCT07376668","Effects of a WhatsApp-assisted Prehabilitation for Patient Undergoing Elective Colorectal Cancer Surgery","WhatsApp-assisted Prehabilitation Programme for Adult Patient Undergoing Elective Colorectal Cancer Surgery - A Randomised Controlled Trial","Inclusion Criteria:\n\n* diagnosis of colorectal-related cancer\n* scheduled for elective colorectal cancer surgery as primary treatment\n* aged 18 years or above\n* expected surgery date more than 21 days\n* able to collaborate in the study and sign the informed consent\n* able to use WhatsApp application\n\nExclusion Criteria:\n\n* identified or known premorbid, that inability to follow the programme\n* able to understand written and spoken Cantonese\u002F Chinese",{"count":207,"type":19},100,[22],"The goals of this study is to evaluate the feasibility and the effects of a WhatsApp-assisted prehabilitation for colorectal cancer patients undergoing elective surgery. The main questions are: If the digital prehabilitation is feasible and acceptable by the colorectal cancer patient prior to elective surgery? If this prehabilitation helps to improve the postoperative complications, length of stay, physical activity and psychological well-being for colorectal cancer patients receiving surgery.\n\nResearcher will compare the prehabilitation plus standard care to standard care only to see if the prehabiliation helps the colorectal cancer patients.\n\nParticipants will: 1) enrolled in a approximate 4 weeks (3 episodes\u002F week) prehabilitation program containing educational information of colorectal cancer, dietary advice, exercises training and psychological podcasting. 2) will answer the survey weekly and after surgery. 3) keep the standard care as per department guidelines",[26],[212],"Prehabilitation","2026-01-29",{"date":215,"type":33},"2026-02-03",{"date":217,"type":19},"2026-01-15",{"date":219,"type":19},"2027-03-31",{"name":221,"class":40},"Tseung Kwan O Hospital, Hong Kong",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":15,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":67},"100616817","feasibility-of-circulating-tumour-dna-ctdna-analysis-using-automated-capillary-blood-sampling-100616817","NCT07310537","Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling","ctDNA TAP","Inclusion Criteria:\n\n* Age ≥ 21 years\n* A history of histologically confirmed (metastatic) colorectal adenocarcinoma\n* Currently diagnosed with (progressive) colorectal liver metastases (CRLM)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patients who are treated and having a response on chemotherapy, as this may have an effect on the investigated biomarker load\n* Illiteracy and\u002For insufficient proficiency of the Dutch language\n* Known medical history of superficial or deep skin infection after venipuncture or intravenous line that required antibiotic treatment and or hospital admittance\n* Known medical history of immunodeficiency or current use of medical immunosuppressants\n* Known medical history of blood-borne diseases such as, but not limited to, the human immunodeficiency virus, hepatitis and viral hemorrhagic fever","21 Years",{"count":231,"type":19},35,"The goal of this observational study is to investigate whether circulating tumor-derived DNA (ctDNA) can be reliably detected and analyzed in blood obtained through automated capillary sampling in adult patients (≥21 years) with colorectal liver metastases (CRLM).\n\nThe main question it aims to answer is:\n\n* Can ctDNA be detected in small volumes of capillary blood collected using an automated sampling device?\n* Do ctDNA levels measured in capillary blood agree with those measured in venous blood from the same patients?\n\nResearchers will compare ctDNA measurements from capillary blood to those from venous blood (reference standard) to see if capillary sampling provides reliable results for ctDNA analysis.\n\nParticipants will:\n\n* Provide a small blood sample through automated capillary collection.\n* Provide a venous blood sample during the same study visit for comparison.",[26,234,235],"Colorectal Liver Metastasis (CRLM)","Circulating Tumor DNA (ctDNA)",[56,234,235,237],"Automated Capillary Blood Sampling","2026-01-02",{"date":240,"type":33},"2026-01-06",{"date":242,"type":33},"2025-11-17",{"date":244,"type":19},"2027-11",{"name":246,"class":40},"Erasmus Medical Center",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":102,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":67},"100598289","colosense-post-approval-study-100598289","NCT07069556","ColoSense Post-Approval Study","ColoSense Post Approval Study","Inclusion Criteria:\n\n* Subject is male or female, ≥45 years of age (subjects aged 18-45 can be enrolled onto the clinical trial but are not eligible for primary endpoint analysis)\n* Subject is able to understand the study procedures, and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a HIPAA medical release form\n* Subject is able and willing to provide stool samples within the 120 days prior to a colonoscopy procedure\n* Subject is able and willing to undergo a colonoscopy after providing a stool sample\n\nExclusion Criteria:\n\n* Subject had any precancerous findings on most recent colonoscopy. This does not include benign, and\u002For hyperplastic polyps of any size\n* Subject has a history or diagnosis of colorectal cancer\n* Subject has a history of aerodigestive tract cancer\n* Subject has had a positive non-invasive screening diagnostic within the associated recommended intervals:\n\n  * Fecal occult blood test or fecal immunochemical test within the previous twelve (12) months\n  * FIT-DNA test within the previous 36 months\n* Subject has had a colonoscopy in the previous nine (9) years.\n* Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease\n* Indication for colonoscopy was due to overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding)\n* Subject has a diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:\n\n  * Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease\n  * Familial adenomatous polyposis (also referred to as \"FAP\", including attenuated FAP)\n  * Hereditary non-polyposis colorectal cancer syndrome (also referred to as \"HNPCC\" of \"Lynch Syndrome\")\n  * Other hereditary cancer syndromes including but are not limited to:\n\n    * Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome\n    * Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis\n    * Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis",{"count":255,"type":19},12500,"The post-approval study (PAS) described here will supplement existing data generated in the CRC-PREVENT clinical trial. The primary outcomes of this supplemental study will include: clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV) of ColoSense.",[26],"2025-11-18",{"date":260,"type":33},"2025-11-21",{"date":262,"type":33},"2025-09-05",{"date":264,"type":19},"2030-09-01",{"name":266,"class":267},"Geneoscopy, Inc.","INDUSTRY",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":20,"phases":277,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":292},"100611755","phase-1-a-study-of-abt-301-plus-tislelizumab-with-bevacizumab-in-pmmrnon-msi-h-locally-advanced-or-mcrc-100611755","NCT07244705","A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR\u002FNon-MSI-H Locally Advanced or mCRC","An Open-label, Multicenter, Phase 1\u002F2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)\u002FNon-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)","Inclusion Criteria:\n\n* Participant must be ≥18 years at the time of signing the informed consent.\n* Participant with pMMR\u002Fnon-MSI-H advanced\u002Frecurrent histologically confirmed CRC with at least one measurable lesion, per RECIST version 1.1.\n* Participant must have received ≥2 lines of prior systemic therapy (including but not limited to chemotherapeutic agents of 5-fluorouracil, oxaliplatin, irinotecan; participant may or may not have received biologic agents such as cetuximab, panitumumab, aflibercept, ramucirumab, bevacizumab; tyrosine kinase inhibitors of regorafenib, fruquintinib).\n\nNOTE: Participants with BRAF V600E, HER2 amplification\u002F mutation, KRAS G12C mutation, NTRK gene fusion, RET fusion, may or may not have received relevant targeted therapy and failed.\n\n* Participant must submit an archival formalin-fixed, paraffin-embedded tumor specimen collected within 5 years before screening. If archival specimens are unavailable, alternative samples, such as colon endoscopy biopsy, are acceptable.\n\nNOTE: For participants who consent to join the exploratory biomarker study, a fresh biopsy sample is required during the screening and treatment periods. Exceptions may be granted if tumor tissue cannot be obtained due to specific circumstances.\n\n* Tumor tissues were identified as pMMR by immunohistochemistry (IHC) method or nonMSI-H by polymerase chain reaction (PCR) (Appendix 13).\n* ECOG Performance Status of 0 or 1.\n* Adequate hematologic and end-organ function, defined by laboratory data obtained within 7 days prior to the first dose of study intervention:\n\n  1. Absolute neutrophil count ≥1.5 × 109\u002FL (1500\u002FμL) without granulocyte colony-stimulating factor support.\n  2. Lymphocyte count \\>0.5 × 109\u002FL (500\u002FµL).\n  3. Platelet count \\>100 × 109\u002FL (100,000\u002FμL), without transfusion.\n  4. Hemoglobin \\>90 g\u002FL (9 g\u002FdL), participants may be transfused to meet this criterion.\n  5. AST, ALT, and ALP \\\u003C2.5 × ULN (must be ≤5 × ULN for participants with liver metastases).\n  6. Total serum bilirubin \\\u003C1.5 × ULN (\\\u003C3 × ULN in the presence of documented Gilbert's syndrome \\[unconjugated hyperbilirubinemia\\] or liver metastases at baseline).\n  7. Creatinine clearance \\>60 mL\u002Fmin.\n  8. Serum albumin ≥30 g\u002FL (3 g\u002FdL).\n  9. International normalized ratio (INR) or activated partial thromboplastic time (aPTT) \\\u003C1.5 × ULN.\n  10. Urine dipstick for proteinuria ≤2+ (within seven days prior to the first dose of study intervention).\n* Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade ≤1 prior to study entry, with the exception of Grade ≤2 chemotherapy-related peripheral neuropathy or any Grade alopecia.\n* Participant must have a negative test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, or human immunodeficiency virus (HIV) antibody.\n\nNOTE: Participants with active hepatitis B virus (HBV) infection are eligible for the study if the following applies: HBV deoxyribonucleic acid (DNA) \\\u003C500 IU\u002FmL within 28 days prior to initiation of study intervention, and anti-HBV treatment (per local standard of care, e.g., entecavir) for a minimum of 14 days prior to study entry and willingness to continue treatment for the length of the study. Participants with positive hepatitis C virus (HCV) test are eligible for the study if they complete their antiviral therapy prior to study entry.\n\n* Contraceptive use by participants or participant partners must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nNOTE: The reliability of sexual abstinence for male and\u002For female enrollment eligibility needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post ovulation methods) and withdrawal are not acceptable methods of contraception.\n\nMale Participants:\n\nA male participant must agree to use a highly effective contraception as detailed in Appendix 4 of this protocol during the intervention period and for at least 90 days after the last dose of study intervention and refrain from donating sperm during this period.\n\nFemale Participants:\n\nA female participant is eligible to participate if she is not pregnant (see Appendix 4), not breastfeeding, and at least one of the following conditions applies:\n\no Not a CBP participant as defined in Appendix 4 and below: surgically sterile (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy as confirmed by review of the participant's medical records, medical examination, or medical history interview), or postmenopausal (defined as no menses for 12 months) without an alternative medical cause with follicle-stimulating hormone (FSH) level in the postmenopausal range ≥1 year.\n\nOR\n\no A CBP participant who agrees to follow the contraceptive guidance in Appendix 4 during the intervention period and for at least 180 days after the last dose of study intervention.\n\n\\- Participant is capable of giving signed informed consent as described in Appendix 1, Section 10.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria:\n\n* History of leptomeningeal disease.\n* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, or ankylosing spondylitis.\n\nEXCEPTIONS:\n\n* Participants with the following conditions are eligible for the study: autoimmune-related hypothyroidism on thyroid-replacement hormone are eligible for the study. Participants with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n* Participants with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., participants with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met: 1. Rash must cover \\\u003C10% of body surface area 2. Disease is well controlled at baseline and requires only low-potency topical corticosteroids 3. No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months.\n\n  * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.\n\nEXCEPTIONS:\n\no History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n\n* Active tuberculosis.\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within three months prior to initiation of study intervention, unstable arrhythmia, or unstable angina.\n\nNOTE: Participants are not eligible for the study if they have or are\n\n1. A marked baseline prolongation of QT\u002FQTc interval (e.g., repeated demonstration of a QTc interval \\>450 milliseconds).\n2. A history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).\n3. Using concomitant medications that prolong the QT\u002FQTc interval. - Major surgical procedure, other than for diagnosis, within four weeks prior to initiation of study intervention, or anticipation of need for a major surgical procedure during the study.\n\n   * History of malignancy other than CRC within five years prior to screening.\n\n   EXCEPTIONS:\n\n   o Participants with malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\>90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer, are eligible for the study.\n\n   \\- Severe infection within four weeks prior to initiation of study intervention, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.\n\n   \\- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications.\n\n   \\- History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.\n   * Known hypersensitivity to Chinese hamster ovary cell products or to any component of the tislelizumab or bevacizumab formulation.\n   * Participant is breastfeeding, has a positive serum pregnancy test at the Screening Visit, or is planning to become pregnant during the study intervention or within at least 120 days after the last dose of study intervention.\n   * Symptomatic, untreated, or actively progressing CNS metastases.\n\n   NOTE: Asymptomatic participants with treated CNS lesions are eligible, provided that all of the following criteria are met:\n   * Measurable disease, per RECIST version 1.1.\n   * Must be present outside the CNS.\n   * The participant has no history of intracranial hemorrhage or spinal cord hemorrhage.\n   * There is no evidence of interim progression between completion of CNS-directed therapy and initiation of study intervention.\n   * The participant has not undergone stereotactic radiotherapy within seven days prior to initiation of study intervention, whole brain radiotherapy within 14 days prior to initiation of study intervention, neurosurgical resection within 28 days prior to initiation of study intervention.\n   * The participant has no ongoing requirement for corticosteroids as therapy for CNS disease.\n\n   NOTE: Anticonvulsant therapy at a stable dose is permitted. Asymptomatic participants with CNS metastases newly detected at screening are eligible for the study after receiving radiotherapy or surgery, with no need to repeat the screening brain scan.\n   * Uncontrolled tumor-related pain:\n\n\u003C!-- -->\n\n1. Participants requiring pain medication must be on a stable regimen at study entry.\n2. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment. Participants should recover from the effects of radiation. There is no required minimum recovery period.\n3. Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment.\n\n   * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).\n   * Treatment with any investigational therapy within 28 days prior to initiation of study intervention.\n   * Treatment with the following pharmaceutical or herbal agents within 14 days prior to initiation of study intervention:\n\n\u003C!-- -->\n\n1. Known to be moderate or strong inhibitors or inducers of CYP3A4 (Appendix 9).\n2. Known to be sensitive or narrow therapeutic index substrates of CYP3A4, CYP2C8, CYP2C9, or CYP2C19 (Appendix 10).\n\n   \\- Prior treatment with any immunotherapy agent, including CD137 agonists or immune checkpoint blockade therapies (such as anti-cytotoxic T-lymphocyte-associated antigen-4 \\[anti-CTLA-4\\], anti-PD-1, and anti-PD-L1 therapeutic antibodies) and has experienced disease progression.\n   * Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor agents) within two weeks prior to initiation of study intervention, or anticipation of need for systemic immunosuppressive medication during study intervention.\n\n   NOTE: Participants who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Medical Monitor approval has been obtained.\n\n   \\- Inadequately controlled arterial hypertension (defined as systolic blood pressure \\>150 mmHg and\u002For diastolic blood pressure \\>100 mmHg), based on an average of three blood pressure readings on two sessions.\n\n   NOTE: Anti-hypertensive therapy to achieve these parameters is allowable.\n\n   \\- Prior history of hypertensive crisis or hypertensive encephalopathy.\n\n   \\- Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within six months prior to initiation of study intervention.\n\n   \\- History of hemoptysis (\\>2.5 mL of bright red blood per episode) within one month prior to initiation of study intervention.\n\n   \\- Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).\n\n   \\- Current or recent (within ten days of first dose of study intervention) use of aspirin (\\>325 mg\u002Fday) or treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol.\n\n   \\- Current or recent (within ten days prior to initiation of study intervention) use of full dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose.\n\n   NOTE: Allowable direct oral anticoagulants for prophylaxis include apixaban, edoxaban, rivaroxaban, and dabigatran. Participants should not be on any other anticoagulant for prophylaxis. Participants taking vitamin K antagonists, such as warfarin, are not eligible for the study.\n\n   \\- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within three days prior to the first dose of study intervention.\n\n   \\- History of abdominal or tracheoesophageal fistula, GI perforation, or intra-abdominal abscess within six months prior to initiation of study intervention.\n\n   \\- History of intestinal obstruction and\u002For clinical signs or symptoms of GI obstruction including sub-occlusive disease-related to the underlying disease or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding within six months prior to initiation of study intervention.\n\n   NOTE: Participants with signs\u002Fsymptoms of sub-\u002Focclusive syndrome\u002Fintestinal obstruction at time of initial diagnosis may be enrolled if they had received definitive (surgical) treatment for symptom resolution.\n\n   \\- Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure.\n   * Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture.\n   * Metastatic disease that involves major airways or blood vessels or centrally located mediastinal tumor masses (\\\u003C30 mm from the carina) of large volume.\n   * History of intra-abdominal inflammatory process within 6 months prior to initiation of study intervention, including but not limited to peptic ulcer disease, diverticulitis, or colitis.\n   * Curative radiotherapy within 28 days and abdominal\u002Fpelvic radiotherapy within 60 days prior to initiation of study intervention, except palliative radiotherapy to bone lesions within seven days prior to initiation of study intervention.\n   * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of study intervention, or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 60 days prior to initiation of study intervention or anticipation of need for major surgical procedure during the course of the study or non-recovery from side effects of any such procedure.\n   * Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID). NOTE: Occasional use of NSAIDs for the symptomatic relief of medical conditions such as headache or fever is allowed. If the Investigator has specific considerations regarding the use of NSAIDs for pain management, it should be discussed with the Sponsor on a case-by-case basis.\n   * Participant cannot swallow oral medications or have a GI illness that may clinically significantly affect the absorption of ABT-301 (e.g., chronic diarrhea with malabsorption).",{"count":276,"type":19},66,[51,278],"PHASE2","The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of ABT-301 in combination with fixed doses of tislelizumab 200 mg IV infusion and bevacizumab 7.5 mg\u002Fkg IV infusion Q3W, in participants with pMMR\u002Fnon-MSI-H colorectal cancer (CRC). It will also determine the maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) of ABT-301.\n\nParticipants will receive ABT-301 administered once daily (QD ±3 hours) or twice daily (Q12H ±3 hours, at least 9 hours apart) with water in 21-day treatment cycles. Tislelizumab 200 mg IV and bevacizumab 7.5 mg\u002Fkg IV Q3W will be given in both parts of the study.",[26,281,282,283],"Colorectal Cancer Metastatic","Colorectal Cancer (CRC)","Immunotherapy",{"date":285,"type":33},"2025-11-24",{"date":287,"type":19},"2025-11",{"date":289,"type":19},"2028-07",{"name":291,"class":267},"Anbogen Therapeutics, Inc.",15,{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":102,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":20,"phases":302,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100605142","the-effectiveness-of-the-mhealth-survivorship-program-on-enhancing-health-related-quality-of-life-among-colorectal-cancer-survivors-100605142","NCT07158671","The Effectiveness of the mHealth Survivorship Program on Enhancing Health-related Quality of Life Among Colorectal Cancer Survivors","The Effectiveness of the mHealth Survivorship Program on Enhancing Health-related Quality of Life Among Colorectal Cancer Survivors: Randomised Controlled Trial","Inclusion Criteria:\n\n* be 18 or older (1);\n* Vietnamese-speaking CRC patients who have completed active treatment and are preparing for discharge (2);\n* provide consent and complete questionnaires independently (3);\n* no metastatic and second cancers (4);\n* using the Android smartphone (5).\n\nExclusion Criteria:\n\n* mental health diseases;\n* receiving anxiety or depression treatment or cognitive\u002Flearning problems.",{"count":301,"type":19},210,[22],"The goal of this clinical trial is to evaluate the effectiveness of the mHealth survivorship program in enhancing health-related quality of life among colorectal cancer survivors. It is hypothesized that participants receiving the mHealth-based survivorship program will report significantly higher levels of health-related quality of life and a lower level of distress, depression, anxiety, fatigue, and bowel dysfunction compared to those in the control group.\n\nParticipants in the intervention group will:\n\nUse the survivorship programme through mHealth every day for 3 months Be called by the healthcare provider every 2 weeks for consultation\n\nParticipants in the control group will receive the usual care",[26],[306,307,308,309,310],"mHealth","Survivorship","Colorectal cancer","Survivors","health-related quality of life","2025-09-02",{"date":313,"type":33},"2025-09-08",{"date":315,"type":19},"2025-09-01",{"date":317,"type":19},"2027-06-30",{"name":319,"class":40},"The Nethersole School of Nursing",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":126,"enrollmentInfo":328,"targetDuration":4,"studyType":20,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":338,"locationsCount":4},"100603252","phase-2-neoadjuvant-therapy-for-locally-advanced-low-rectal-cancer-smarti-rc01-100603252","NCT07134101","Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","Neoadjuvant Chemoradiotherapy Combined With Serplulimab With or Without Bevacizumab for Locally Advanced Rectal Cancer: A Single-Center, Open-Label, Phase II Randomized Trial","SMARTi-RC01","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for the study:\n\n1. Age: 18 to 75 years old.\n2. Diagnosis: Pathologically confirmed rectal adenocarcinoma with proficient mismatch repair (pMMR) \u002F microsatellite stable (MSS) status, based on biopsy of the primary tumor.\n3. Disease Stage: Untreated, preoperative clinical stage cT2-T4 and\u002For N+, M0 (AJCC 8th edition), unsuitable for initial local excision to achieve radical cure.\n4. Tumor Location: Tumor within 8 cm from the anal verge, or assessed by surgeons as not suitable for immediate sphincter-preserving surgery.\n5. Organ Preservation Intent: Strong desire for sphincter preservation and willingness to accept close surveillance for at least 2 years after chemoradiotherapy.\n6. Surgical Candidacy: Agrees to undergo radical surgery and judged by surgeon to have no contraindication to surgery.\n7. Cancer History: No concurrent multiple primary malignancies.\n8. Measurable Lesions: At least one measurable or evaluable lesion according to RECIST v1.1 criteria.\n9. Life Expectancy: ≥ 3 months.\n10. Performance Status: ECOG performance status score of 0-1.\n11. Compliance: Good compliance and willingness to sign written informed consent.\n\nExclusion Criteria:\n\nParticipants will be excluded if any of the following conditions apply:\n\n1. Molecular Subtype: Rectal cancer with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status.\n2. Autoimmune Disease: Active, known, or suspected autoimmune disease.\n3. Immunodeficiency: Known history of primary immunodeficiency.\n4. Transplant History: History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n5. Pregnancy or Lactation: Pregnant or breastfeeding women.\n6. Urgent Surgical Indications: Intestinal perforation, gastrointestinal bleeding, or other conditions requiring emergency surgery.\n7. Uncontrolled Comorbidities, including but not limited to:\n\n   HIV infection (HIV antibody positive) Active or poorly controlled severe infection Active hepatitis Severe or uncontrolled systemic diseases (e.g., severe psychiatric or neurological disorders, epilepsy, dementia, unstable or decompensated respiratory, cardiovascular, hepatic, or renal disease, uncontrolled hypertension ≥ CTCAE Grade 2 despite medication) Active bleeding or recent thrombotic disease requiring therapeutic anticoagulation, or bleeding tendency, or coagulation abnormalities (INR \\> 1.5 × ULN, APTT \\> 1.5 × ULN)\n8. Laboratory Abnormalities at Baseline:\n\n   Hemoglobin \\\u003C 80 g\u002FL Absolute neutrophil count (ANC) \\\u003C 1.5 × 10⁹\u002FL Platelets \\\u003C 80 × 10⁹\u002FL ALT or AST \\> 2.5 × ULN ALP \\> 2.5 × ULN Total bilirubin ≥ 1.5 × ULN Serum creatinine ≥ 1 × ULN\n9. Allergy: Known hypersensitivity to any component of the investigational drugs.\n10. Other Clinical Trial Participation: Currently enrolled in another interventional drug clinical trial.\n11. Other Conditions: Any other condition judged by the investigator to make the patient unsuitable for the study.",{"count":329,"type":19},138,[278],"The goal of this clinical trial is to learn if combining serplulimab (PD-1 inhibitor) with bevacizumab and short-course total neoadjuvant therapy (TNT) works to treat locally advanced mid-to-low rectal cancer in adults. It will also learn about the safety of this combination.\n\nThe main questions it aims to answer are:\n\nDoes adding bevacizumab to serplulimab and TNT increase the complete remission rate (cCR + pCR) compared with serplulimab and TNT alone? What medical problems do participants have when receiving these treatments?\n\nResearchers will compare:\n\nExperimental group: serplulimab + bevacizumab + chemotherapy + short-course radiotherapy Control group: serplulimab + chemotherapy + short-course radiotherapy\n\nParticipants will:\n\nReceive either the experimental or control regimen for about 4-5 months before surgery or a watch-and-wait approach if complete response is achieved Undergo treatment in cycles that include chemotherapy, immunotherapy (and bevacizumab if in the experimental group), and short-course radiotherapy Visit the clinic regularly for check-ups, blood tests, imaging, endoscopy, and to monitor side effects Be followed for up to 5 years after treatment to assess cancer control, organ preservation, and survival outcomes",[26],"2025-08-24",{"date":335,"type":33},"2025-08-29",{"date":315,"type":19},{"date":117,"type":19},{"name":339,"class":40},"The First Affiliated Hospital with Nanjing Medical University",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":20,"phases":350,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":67},"100599674","short-term-nutritional-enhancement-combined-with-health-education-in-postoperative-colorectal-cancer-patients-a-randomized-controlled-trial-100599674","NCT07087561","Short-Term Nutritional Enhancement Combined With Health Education in Postoperative Colorectal Cancer Patients: A Randomized Controlled Trial","The Effects and Mechanisms of Short-Term Nutritional Enhancement Combined With Health Education on Clinical Outcomes in Postoperative Patients With Colorectal Cancer: A Multicenter, Open-Label, Randomized Controlled Trial","NUTRI-CRC","Inclusion Criteria:\n\n* Signed informed consent\n* Age ≥ 18 years\n* Pathologically confirmed diagnosis of colon or rectal cancer\n* Mentally alert and capable of communication\n* Willing to participate in follow-up, with an estimated life expectancy of more than 6 months\n* Cancer stage IIa, IIb, or IIIa\n\nExclusion Criteria:\n\n* Nutritional risk screening score of mPG-SGA \\\u003C 2 or NRS-2002 \\\u003C 3\n* Diagnosed with AIDS\n* History of organ transplantation\n* Pregnant or breastfeeding women\n* Concurrent participation in another interventional clinical trial\n* Inability to care for oneself independently\n* Inability to engage in physical activity during the perioperative period\n* Severe comorbid conditions (e.g., uncontrolled cardiovascular disease, severe hepatic or renal dysfunction)\n* Known allergy or intolerance to components of the nutritional supplements used in the study",{"count":349,"type":19},360,[22],"This clinical study aims to evaluate whether short-term personalized nutritional support, when combined with structured health education, can improve nutritional status, quality of life, and clinical outcomes in patients who have undergone surgery for colorectal cancer (CRC). Colorectal cancer is one of the most common cancers worldwide, and many patients experience malnutrition and poor physical condition during treatment, which can negatively affect recovery and long-term survival.\n\nIn this multicenter, randomized, controlled clinical trial, approximately 360 postoperative CRC patients will be enrolled and randomly assigned to one of four groups: (A) nutritional enhancement combined with health education, (B) health education alone, (C) nutritional enhancement alone, or (D) standard care (control group). Nutritional support will include individualized diet counseling and oral nutritional supplements tailored to each patient's needs. Health education will be delivered using an \"Internet Plus\" approach, including weekly educational videos and expert consultations focusing on nutrition, physical activity, and mental health.\n\nThe primary objectives are to determine whether these interventions can improve patients' short-term nutritional status and quality of life. Secondary outcomes include the impact of interventions on long-term survival, treatment-related side effects, patient adherence to nutrition recommendations, and psychological well-being.\n\nThis study will also investigate the biological mechanisms underlying the clinical effects by analyzing changes in the gut microbiome, blood-based metabolic profiles, and immune responses. Blood, stool, and tumor tissue samples will be collected and analyzed using advanced techniques, including untargeted metabolomics, metagenomics, and single-cell sequencing.\n\nThis trial is designed to provide evidence for the integration of nutritional strategies into routine cancer care, and to guide the development of more personalized, effective nutrition-based therapies for colorectal cancer patients. Participants will be followed for up to annually up to 5 years to evaluate both clinical outcomes and biological markers of response.",[26,353],"Malnutrition or Risk of Malnutrition",[56,355,356,357,358,359,360],"Nutrition Support","Health Education","Patient-Reported Outcomes","Nutritional Risk","Cancer Rehabilitation","Randomized Controlled Trial","2025-07-18",{"date":363,"type":33},"2025-07-28",{"date":365,"type":33},"2024-10-10",{"date":367,"type":19},"2030-10-10",{"name":369,"class":40},"Xiaoqin Luo"]